Experience with triple-drug therapy in a pharmacological erection program.
A group of 170 impotent men achieved usable erections during a 26-month period with a combination of papaverine, phentolamine and prostaglandin E1 (triple-drug therapy) injected intracorporeally. Of the patients 146 elected to enter a pharmacological erection program using this combination. Patient age ranged from 24 to 85 years and the average duration on the program was 11.2 months. Average injection volume was 0.36 cc per injection (range 0.1 to 1). Among those patients managed by our nurse clinician, only 3 episodes of priapism were encountered (1.7%). Scarring was documented in 7 of 170 patients (4.2%) 1 week to 21 months after starting the injections. Pain was encountered in 6 of 170 patients (3.5%). A superior dose response coupled with a low incidence of priapism, pain and scarring have led us to use triple-drug therapy as our agent of choice in the pharmacological management of erectile dysfunction.
Govier
F E
FE
Department of Urology, Virginia Mason Medical Center, Seattle, Washington.
McClure
R D
RD
Weissman
R M
RM
Gibbons
R P
RP
Pritchett
T R
TR
Kramer-Levien
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000008:administration & dosage* / Q000627:therapeutic use; D002921:Cicatrix / Q000209:etiology; D003365:Costs and Cost Analysis; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage* / Q000627:therapeutic use; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000473:pathology; D010646:Phentolamine / Q000008:administration & dosage* / Q000627:therapeutic use; D011317:Priapism / Q000139:chemically induced; D012646:Self Administration
D004338:Drug Combinations; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine